Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

As OS Therapies prepares to take its bacteria-based lung cancer therapy to the FDA for approval, the biotech has been ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit Therapeutics (NASDAQ:SMMT) has entered a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (NYSE:PFE) antibody drug conjugates across multiple ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

In this video, Tanya Dorff, MD discusses the current state of the pipeline for developing castration-resistant prostate cancer treatments.

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

This makes ROR-1 an attractive therapeutic target for anti-cancer drug development. RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR-1, site specific conjugation to deliver a ...